Search

Endo launches ready-to-use vasopressin injection in pre-mix bottles


  • First and only manufacturer-prepared, FDA approved vasopressin in a premixed ready-to-use (RTU) format

  • RTU format does not require diluting, or transferring, which may reduce waste and chance of preparation error that could impact a patient's health

  • Two-year shelf life1, with up to 12 months at room temperature2*, may offer enhanced health systems' inventory management


Endo International plc (NASDAQ: ENDP) announced today that its Par Sterile Products business has begun shipping VASOSTRICT®, vasopressin injection, USP, in ready-to-use 100 mL pre-mix bottles. It's the first and only ready-to-use formulation of the drug. "Our partners in healthcare are working harder than ever; this new ready-to-use bottle allows them to focus more of their time on what matters most—patient care," said Scott Sims, Senior Vice President and General Manager, Sterile Products at Endo. "Our team remains dedicated to meeting the evolving needs of healthcare providers."

Ready-to-use, or RTU, products help streamline operations for hospitals by eliminating the need to prepare or transfer the product before patient administration. This may reduce waste and costs, optimize convenience and workflow, and heighten accuracy and compliance by reducing the chance for preparation error—all of which support quality patient care. This new VASOSTRICT® formulation has a two-year shelf life1, with up to 12 months at room temperature2*, which may offer enhanced inventory management in addition to the other advantages of an RTU formulation/presentation.

* Store between 2°C and 8°C (36°F and 46°F). Vials may be held up to 12 months upon removal from refrigeration to room temperature storage conditions (20°C to 25°C [68°F to 77°F]).

About Endo Endo (NASDAQ: ENDP) is a specialty pharmaceutical company committed to helping everyone we serve live their best life through the delivery of quality, life-enhancing therapies. Our decades of proven success come from passionate team members around the globe collaborating to bring the best treatments forward. Together, we boldly transform insights into treatments benefiting those who need them, when they need them. Learn more at www.endo.com or connect with us on LinkedIn.

About Par Pharmaceutical Par Pharmaceutical develops, manufactures and markets safe, innovative and cost-effective generic pharmaceutical and branded injectable products that help improve patient quality of life. Par, among the top leaders in the U.S. generics industry, possesses an expanding portfolio that includes sterile injectables, alternative dosage forms and other differentiated products. Par Pharmaceutical is an Endo company. Learn more at www.parpharm.com. References:

  1. Data on File. Vasostrict® Stability Summary Report. Par Sterile Products, LLC; December 8, 2021.

  2. Vasostrict® Prescribing Information 04/2021.

SOURCE Endo International plc